Craig-Hallum Analyst Maintains Buy Rating on Personalis with $7 Price Target

Personalis (PSNL) received a Buy rating and $7.00 price target from Craig-Hallum analyst John Wilkin. The company has a Strong Buy consensus and $6.89 price target, representing a 52.43% upside. PSNL's market cap is $399.9M and has a P/E ratio of -3.54. Corporate insider sentiment is negative, with 16 insiders selling shares over the past quarter.

Personalis Inc. (PSNL), a biotechnology company specializing in molecular diagnostics, reported its Q2 2025 earnings on August 5, 2025. The company posted a 23.8% year-over-year decline in revenue to $17.2 million and a slight improvement in per-share loss to $0.23, but net losses widened to $20.06 million. The company revised its 2025 revenue guidance to $70–$80 million from the previous $80–$90 million range, citing biopharma project delays and uncertainty around reimbursement timelines.

Despite the revenue decline, analysts maintain a positive outlook on Personalis. HC Wainwright & Co. has maintained a "Buy" rating for Personalis but lowered its price target to $8.50 from $9.00 [1]. Analyst John Wilkin from Craig-Hallum also issued a "Buy" rating with a $7.00 price target [2]. Needham analyst Michael Matson maintained a "Buy" rating with a $7.00 price target, citing strong growth in the molecular testing segment and strategic focus on reimbursement for NeXT Personal products [3].

The company's CEO, Christopher M. Hall, highlighted strong clinical momentum with a 59% sequential clinical test volume growth and progress toward Medicare coverage for two indications by year-end. Gross margin was 27.6% for Q2, down from 35.6% year-over-year, with unreimbursed clinical test costs impacting margin by approximately 12% [1].

Personalis' corporate insider sentiment is negative, with 16 insiders selling shares over the past quarter. However, the company's market cap is $399.9 million, and its P/E ratio is -3.54. The Strong Buy consensus suggests a 52.43% upside to the current $6.89 price target [2].

References:
[1] https://www.ainvest.com/news/hc-wainwright-maintains-buy-rating-personalis-lowers-price-target-8-50-2508/
[2] https://www.tipranks.com/news/ratings/personalis-strong-molecular-testing-growth-and-strategic-mrd-focus-support-buy-rating-ratings
[3] https://www.quiverquant.com/news/PERSONALIS+Earnings+Results%3A+%24PSNL+Reports+Quarterly+Earnings